2026-06-14T05:18:50Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/182712024-11-28T15:02:43Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927col_20.500.12105_16968
Repisalud
author
Saludas, Laura
author
Oliveira, Cláudia C.
author
Roncal, Carmen
author
Ruiz-Villalba, Adrián
author
Prósper, Felipe
author
Garbayo, Elisa
author
Blanco-Prieto, María J.
authoraffiliation
[Saludas,L; Garbayo,E; Blanco-Prieto,MJ] Department of Pharmaceutical Technology and Chemistry, Faculty of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain. [Saludas,L; Roncal,C; Prósper,F; Garbayo,E; Blanco-Prieto,MJ] Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain. [Oliveira,CC; Ruiz-Villalba,A] Department of Animal Biology, Institute of Biomedicine of Málaga (IBIMA), Faculty of Science, University of Málaga, Málaga, Spain. [Oliveira,CC; Ruiz-Villalba,A] Andalusian Centre for Nanomedicine and Biotechnology (BIONAND), Málaga, Spain. [Roncal,C] Laboratory of Atherothrombosis, Program of Cardiovascular Diseases, CIMA, University of Navarra, Pamplona, Spain. [Roncal,C] Centro de Investigación Biomédica en Red (CIBERCV), Carlos III Institute of Health, Madrid, Spain. [Prósper,F] Program of Regenerative Medicine, CIMA, University of Navarra, Pamplona, Spain. [Prósper,F] Cell Therapy Area and Haematology Department, Clínica Universidad de Navarra, Pamplona, Spain. [Prósper,F] Centro de Investigación Biomédica en Red (CIBERONC), Carlos III Institute of Health, Madrid, Spain.
2024-02-19T15:25:17Z
2024-02-19T15:25:17Z
2021-02-25
10.3390/nano11030570
2079-4991
Nanomaterials
http://hdl.handle.net/10668/3409
33668836
http://hdl.handle.net/20.500.12105/18271
Extracellular vesicles (EVs) are constituted by a group of heterogeneous membrane vesicles secreted by most cell types that play a crucial role in cell-cell communication. In recent years, EVs have been postulated as a relevant novel therapeutic option for cardiovascular diseases, including myocardial infarction (MI), partially outperforming cell therapy. EVs may present several desirable features, such as no tumorigenicity, low immunogenic potential, high stability, and fine cardiac reparative efficacy. Furthermore, the natural origin of EVs makes them exceptional vehicles for drug delivery. EVs may overcome many of the limitations associated with current drug delivery systems (DDS), as they can travel long distances in body fluids, cross biological barriers, and deliver their cargo to recipient cells, among others. Here, we provide an overview of the most recent discoveries regarding the therapeutic potential of EVs for addressing cardiac damage after MI. In addition, we review the use of bioengineered EVs for targeted cardiac delivery and present some recent advances for exploiting EVs as DDS. Finally, we also discuss some of the most crucial aspects that should be addressed before a widespread translation to the clinical arena.
eng
Cardiovascular diseases
Myocardial infarction
Cardiac repair
Extracellular vesicles
Exosomes
Drug delivery
Cargo loading
Targeting
Enfermedades cardiovasculares
Infarto del miocardio
Vesículas extracelulares
Exosomas
Sistemas de liberación de medicamentos
Extracellular Vesicle-Based Therapeutics for Heart Repair
review article